Draig Therapeutics

News

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.